A molecular cytogenetic analysis of 7q31 in prostate cancer

Cancer Research

Volumn 58, Issue 4, 1998, Pages 759-766

  Jenkins, Robert B ^a   Qian, Junqi ^a   Lee, Hyun K ^a   Huang, Haojie ^a   Hirasawa, Kiyoshi ^a   Bostwick, David G ^a   Proffitt, John ^b   Wilber, Kim ^b   Lieber, Michael M ^a   Liu, Wanguo ^a   Smith, David I ^a  

^a MAYO CLINIC   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHROMOSOME 7Q; CLINICAL ARTICLE; CYTOGENETICS; DNA PROBE; GENE MUTATION; HUMAN; HUMAN CELL; MALE; MALE GENITAL TRACT CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER;

CHROMOSOME ABERRATIONS; CHROMOSOME BREAKAGE; CHROMOSOME DELETION; CHROMOSOME FRAGILE SITES; CHROMOSOME FRAGILITY; CHROMOSOMES, HUMAN, PAIR 7; DNA MUTATIONAL ANALYSIS; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MONOSOMY; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; TRISOMY;

EID: 0032519595     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Bandyk, M. G., Zhao, L., Troncoso, P., Pisters, L. L., Palmer, J. L., von Eschenbach, A. C., Chung, L. W. K., and Liang, J. C. Trisomy 7: a potential cytogenetic marker of human prostate cancer progression. Genes Chromosomes Cancer, 9: 19-27, 1994.
2. Qian, J., Bostwick, D. G., Takahashi, S., Borell, T. J., Herath, J. F., Lieber, M. M., and Jenkins, R. B. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res., 55: 5408-5414, 1995.
3. Takahashi, S., Qian, J., Brown, J. A., Alcaraz, A., Bostwick, D. G., Lieber, M. M., and Jenkins, R. B. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization. Cancer Res., 54: 3574-3579, 1994.
4. Alcaraz, A., Takahashi, S., Brown, J. A., Herath, J. F., Bergstralh, E., Larson-Keller, J., Lieber, M. M., and Jenkins, R. B. Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res., 54: 3998-4002, 1994.
5. Persons, D. L., Gibney, D. J., Hatzmann, J. A., Lieber, M. M., Farrow, G. M., and Jenkins, R. B. Use of fluorescence in situ hybridization for deoxyribonucleic acid ploidy analysis of prostatic carcinoma. J. Urol., 150: 120-125, 1993.
6. Brothman, A. R., Peehl, D. M., and McNeal, J. E. Frequency and pattern of karyotypic anomalies in human prostate cancer. Cancer Res., 50: 3795-3803, 1990.
7. Lundgren, R., Mandahl, N., Heim, S., Limon, J., Henrikson, H., and Mitelman, F. Cytogenetic analysis of 57 primary prostatic adenocarcinomas. Genes Chromosomes Cancer, 4: 6-24, 1992.
8. Collard, J. G., van de Poll, M., Scheffer, A., Roos, E., Hopman, A. H. M., Geurts van Kessel, A. H. M., and van Dongen, J. J. M. Location of genes involved in invasion and metastasis on human chromosome 7. Cancer Res., 47: 6666-6670, 1987.
9. n microsatellite repeat D7S522 is the most commonly deleted region in human primary breast cancer. Proc. Natl. Acad. Sci. USA, 91: 12155-12158, 1994.
10. Zenklusen, J. C., Thompson, J. C., Klein-Szanto, A. J. P., and Conti, C. J. Frequent loss of heterozygosity in human primary squamous cell and colon carcinomas at 7q31.1: evidence for a broad range tumor suppressor gene. Cancer Res., 55: 1347-1350, 1995.
11. Zenklusen, J. C., Thompson, J. C., Troncoso, P., Kagan, J., and Conti, C. J. Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. Cancer Res., 54: 6370-6373, 1994.
12. Latil, A., Cusseno, O., Fournier, G., Baron, J. C., and Lidereau, R. Loss of heterozygosity at 7q31 is a frequent and early event in prostate cancer. Clin. Cancer Res., 1: 1385-1389, 1995.
13. Takahashi, S., Shan, A. L., Ritland, S. R., Delacey, K. A., Bostwick, D. G., Lieber, M. M., Thibodeau, S. N., and Jenkins, R. B. Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res., 55: 5115-5119, 1995.
14. 0 prostate cancer. Genes Chromosomes Cancer, in press, 1998.
15. Alers, C. A., Krijtenburg, P. J., Vissers, K. J., Bosman, F. T., van der Kwast, T. H., and Dekken, H. Interphase cytogenetics of prostatic adenocarcinoma and precursor lesions: analysis of 25 radical prostatectomies and 17 adjacent prostatic intraepithelial neoplasias. Genes Chromosomes Cancer, 12: 241-250, 1995.
16. Jenkins, R. B., Qian, J., Lieber, M. M., and Bostwick, D. G. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization (FISH). Cancer Res., 57: 524-531, 1997.
17. Qian, J., Bostwick, D. G., Takahashi, S., Brown, J. A., Lieber, M. M., and Jenkins, R. B. Comparison of fluorescence in situ hybridization analysis of isolated nuclei and routine histologic sections from paraffin-embedded prostatic adenocarcinoma specimens. Am. J. Pathol., 149: 1193-1199, 1996.
18. Berger, R., Bloomfield, C. D., and Sutherland, G. R. Report of the committee on chromosome rearrangements in neoplasia and on fragile sites (HGM8). Cytogenet. Cell Genet., 40: 490-535, 1985.
19. Huang, H., Qian, C., Jenkins, R. B., and Smith, D. I. FISH mapping of YAC clones at human chromosomal band 7q31.2: identification of YACS spanning FRA7G within the common region of LOH in breast and prostate cancer. Genes Chromosomes Cancer, in press, 1998.
20. Liu, W., James, D. C., Frederick, L., Alderete, B. E., and Jenkins, R. B. PTEN/ MMAC1 mutations and epidermal growth factor receptor amplification in glioblastomas. Cancer Res., 57: 5254-5257, 1997.
21. Hayward-Lester, A., Oefner, P. J., Sabatini, S., and Doris, P. A. Accurate and absolute quantitative measurement of gene expression by single-tube RT-PCR and HPLC. Genome Res., 5: 494-499, 1995.
22. Schmidt, L., Duh, F. M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., Allikmets, R., Chidambaram, A., Bergerheim, U. R., Feltis, J. T., Casadevall, C., Zamarron, A., Orcutt, M. L., Stackhouse, T., Lipan, J., Slife, L., Brauch, H., Decker, J., Niehans, G., Hughson, M. D., Moch, H., Storkel, S., Lerman, M. I., Linehan, W. M., and Zbar, B. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet., 16: 68-73, 1997.
23. Visakorpi, T., Kallioniemi, A. H., Syvanen, A. C., Hyytinen, E. R., Karhu, R., Tammela, , Isola, J. J., and Kallioniemi, O. P. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res., 55: 342-347, 1995.
24. Cher, M. L., Bova, G. S., Moore, D. H., Small, E. J., Carroll, P. R., Pin, S. S., Epstein, J. I., Isaacs, W. B., and Jensen, R. H. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res., 56: 3091-3102, 1996.
25. Edelson, M. I., Scherer, S. W., Tsui, L. C., Welch, W. R., Bell, D. A., Berkowitz, R. S., and Mok, S. C. Identification of a 1300-kilobase deletion unit on chromosome 7q31.3 in invasive epithelial ovarian carcinomas. Oncogene, 14: 2979-2984, 1997.
26. Abrahamson, G. M., Rack, K., Oscier, D. G., Fichett, M., Buckle, V. J., and Wainscoat, J. S. Comparison of cytogenetic and restriction fragment length polymorphism analyses for the detection of loss of chromosome material in clonal hemopoietic disorders. Am. J. Hematol., 42: 171-176, 1993.
27. Bieche, I., Champeme, M. H., Matifas, F., Hacene, K., Callahan, R., and Lidereau, R. Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet, 339: 139-143, 1992.
28. Deng, G., Chen, L. C., Schott, D. R., Thor, A., Bhargava, V., Ljung, B. M., Chew, K., and Smith, H. S. Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res., 54: 499-505, 1994.
29. Lin, J. C, Scherer, S. W., Tougas, L., Traverso, G., Tsui, L., Andrulis, I. L., Jothy, S., and Park, M. Detailed deletion mapping with a refined physical map of 7q31 localizes a putative tumor suppressor gene for breast cancer in the region of MET. Oncogene, 13: 2001-2008, 1996.
30. Yunis, J. J., and Soreng, A. L. Constitutive fragile sites and cancer. Science (Washington DC), 226: 1199-1204, 1984.
31. Paradee, W., Wilke, C. M., Wang, L., Shridhar, R., Mullins, C. M., Hoge, A., Glover, T. W., and Smith, D. I. A 350-kb cosmid contig in 3p14.2 that crosses the t(3;8) hereditary renal cell carcinoma translocation breakpoint and 17 aphidicolin-induced FRA3B breakpoints. Genomics, 35: 87-93, 1996.
32. Zimonjic, D. B., Druck, T., Ohta, M., Kastury, K., Carlo, M. C., and Popescu, N. C. Positions of chromosome 3p14.2 fragile sites (FRA3B) within the FIHT gene. Cancer Res., 57: 1166-1170, 1997.
33. Coquelle, A., Pipiras, E., Toledo, F., Buttin, G., and Debatisse, M. Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplifications. Cell, 89: 215-225, 1997.
34. Hofstra, R. M., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W. M., van Amstel, H. K. P., Romeo, G., Lips, C. J. M., and Buys, C. H. C. M. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature (Lond.), 367: 375-376, 1994.
35. Eng, C., Smith, D. P., Mulligan, L. M., Healey, C. S., Zvelebil, M. J., Stonehouse, T. J., Ponder, M. A., Jackson, C. E., Waterfield, M. D., and Ponder, B. A. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene, 10: 509-513, 1995.
36. Ponzetto, C., Giordano, S., Peverali, F., Della Valle, G., Abate, M. L., Vaula, G., and Comoglio, P. M. C-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. Oncogene, 6: 553-559, 1991.
37. Bremner, R., and Balmain, A. Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell, 61: 407-417, 1990.
38. Wirchubsky, Z., Wiener, F., Spira, J., Sumegi, J., and Klein, G. Triplication of one chromosome no. 15 with an altered c-myc homologue in a T-cell lymphoma line of AKR origin (TIKAUT). Int. J. Cancer, 33: 477-481, 1984.
39. Humphery, P. A., Zhu, X., Zarnegar, R., Swanson, P. E., Ratliff, T. L., Vollmer, R. T., and Day, M. L. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am. J. Pathol., 147: 386-396, 1995.
40. Kallioniemi, A., Kallioniemi, O. P., Piper, J., Tanner, M., Stokke, T., Chen, L., Smith, H. S., Pinket, D., Gray, J. W., and Waldman, F. M. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc. Natl. Acad. Sci. USA, 91: 2156-2160, 1994.
41. Tanner, M. M., Tirkkonen, M., Kallioniemi, A., Isola, J., Kuukasjarvi, T., Collins, C., Kowbel, D., Guan, X. Y., Trent, J., Gray, J. W., Meltzer, P., and Kallioniemi, O. P. Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res., 56: 3441-3445, 1996.